Key Performance
More- Earnings Score: N/A
- Momentum Score: 15
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
RxSight, Inc. announced preliminary 2025 full-year revenue of $134.5 million, exceeding guidance, driven by 109,615 Light Adjustable Lens procedures (12% increase YoY) and expansion of its installed base to 1,134 Light Delivery Devices. The company also appointed Mark Wilterding as Chief Financial Officer, bringing 25+ years of medtech financial leadership experience from Edwards Lifesciences.
01/11/2026, 9:30 AM • GlobeNewswire
DJS Law Group is investigating RxSight, Inc. for potential securities law violations after the company reported significant financial declines, including reduced sales of Light Delivery Devices and lowered annual financial guidance.
09/22/2025, 4:24 AM • Benzinga
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight
Faruqi & Faruqi is investigating potential securities law violations by RxSight after the company reported significant sales declines and lowered financial guidance, causing its stock price to drop 37.8%.
09/21/2025, 7:22 AM • GlobeNewswire
Rosen Law Firm is alerting RxSight investors about a September 22, 2025 deadline for a securities class action lawsuit, alleging the company made false statements about customer adoption and growth metrics.
09/21/2025, 6:45 AM • GlobeNewswire
Rosen Law Firm reminds RxSight investors who purchased securities between May 7, 2024 and July 8, 2025 about an upcoming September 22, 2025 deadline for a securities class action lawsuit, alleging the company misrepresented its growth potential and market performance.
09/21/2025, 6:45 AM • GlobeNewswire
Rosen Law Firm alerts investors of Replimune Group and RxSight who suffered losses over $100,000 about an upcoming September 22, 2025 deadline for filing securities class action lawsuits related to allegedly misleading statements.
09/21/2025, 6:09 AM • GlobeNewswire
RxSight, a medical device company specializing in light adjustable intraocular lenses, faces a securities fraud lawsuit after experiencing significant stock declines due to reported adoption challenges and market softening in its product line.
09/20/2025, 7:36 AM • GlobeNewswire
The Schall Law Firm is pursuing a class action lawsuit against RxSight, Inc. for alleged securities fraud, claiming the company made false and misleading statements about its financial performance and product demand between November 2024 and July 2025.
09/18/2025, 5:43 AM • Benzinga
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight
Faruqi & Faruqi is investigating potential securities claims against RxSight after the company reported significant sales declines and lowered financial guidance, causing its stock price to drop 37.8%.
09/17/2025, 11:23 PM • GlobeNewswire
A securities class action lawsuit has been filed against RxSight, Inc. for allegedly making false statements and failing to disclose material adverse facts about the company's business during the period of November 7, 2024 to July 8, 2025.
09/17/2025, 8:00 PM • GlobeNewswire
A class action lawsuit has been filed against RxSight alleging false statements about product demand and financial guidance, with stock price dropping 38% after revealing significant sales declines and adoption challenges.
09/17/2025, 5:55 PM • GlobeNewswire
A class action lawsuit has been filed against RxSight alleging the company made false statements about its business performance, product demand, and financial guidance during the period of November 7, 2024 to July 8, 2025.
09/17/2025, 4:00 PM • GlobeNewswire
Rosen Law Firm alerts RxSight investors about a securities class action lawsuit alleging misleading statements about company growth and performance during May 7, 2024 to July 8, 2025 period.
09/17/2025, 1:52 PM • GlobeNewswire
RxSight faces class action lawsuit alleging misleading statements about product adoption, sales challenges, and financial guidance, resulting in significant stock price decline.
09/16/2025, 4:54 PM • GlobeNewswire
RxSight faces a class action lawsuit alleging false financial statements and misleading investors about product demand and sales performance, with stock price dropping 38% after revealing significant revenue and adoption challenges.
09/15/2025, 5:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.